title: Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure.
abstract: BACKGROUND
  Malnutrition is very prevalent among patients with chronic renal failure. The role of derangements in the gut-brain axis for regulation of appetite in the genesis of anorexia of these patients has not been adequately investigated. Design. Following a randomized, crossover design, we analysed plasma levels of peptide YY (PYY)(1-36) and PYY(3-36) both fasting and after a standardized oral mixed meal or intraperitoneal glucose infusion in 10 stable uraemic patients undergoing peritoneal dialysis and 8 healthy controls, matched for age, gender and body mass index. Main results. Median baseline plasma levels of PYY(1-36) in the different provocation tests oscillated between 406 and 460 pg/mL in patients, as compared with 73 and 100 pg/mL in controls (P < 0.001). Corresponding values for PYY(3-36) oscillated between 235 and 267 pg/mL in patients, versus 56 and 70 pg/mL in controls (P < 0.001). The association of high levels of PYY(3-36) and normal levels of acylated ghrelin (when compared with healthy controls) configurated a markedly pro-anorexigenic pattern in patients. Neither oral intake nor intraperitoneal glucose resulted in significant changes in plasma levels of PYY(1-36) or PYY(3-36) in subjects with renal failure, in contrast with the expected postprandial rise observed in healthy controls (41% for PYY(1-36), P = 0.04 and 32% for PYY(3-36), P = 0.02, median values).
  
  
  CONCLUSIONS
  Baseline plasma levels of PYY(1-36) or PYY(3-36) are markedly elevated in patients with renal failure undergoing peritoneal dialysis. Provocation studies disclose a marked disregulation in the postprandial secretion of these anorexigenic peptides, when compared with healthy controls. These findings may contribute to clarify the complex pathogenesis of anorexia of chronic renal failure.
authors.affiliation: Department of Medicine, University of A Coruña, University Hospital Juan Canalejo, Coruña, Spain. mfontan@canalejo.org
authors.forename: Miguel
authors.initials: M
authors.lastname: Pérez-Fontán
authors.forename: Fernando
authors.initials: F
authors.lastname: Cordido
authors.forename: Ana
authors.initials: A
authors.lastname: Rodríguez-Carmona
authors.forename: Manuel
authors.initials: M
authors.lastname: Penín
authors.forename: Helena
authors.initials: H
authors.lastname: Díaz-Cambre
authors.forename: Andrés
authors.initials: A
authors.lastname: López-Muñiz
authors.forename: Susana
authors.initials: S
authors.lastname: Sangiao-Alvarellos
authors.forename: Jesús
authors.initials: J
authors.lastname: García-Buela
mesh_terms: D000328:Adult; D000368:Aged; D000855:Anorexia / Q000209:etiology / Q000503:physiopathology; D001066:Appetite / Q000502:physiology; D016022:Case-Control Studies; D002908:Chronic Disease; D018592:Cross-Over Studies; D015314:Dialysis Solutions / Q000494:pharmacology*; D005260:Female; D005526:Food, Formulated; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D044342:Malnutrition / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D019894:Peptide YY / Q000097:blood*; D010530:Peritoneal Dialysis; D051437:Renal Insufficiency / Q000097:blood* / Q000150:complications / Q000628:therapy*
chemical_list: D015314:Dialysis Solutions; D019894:Peptide YY; D005947:Glucose